Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.

NCT03329508 is registered in ClinicalTrials.gov with Pharma Two B Ltd. as lead sponsor.

NCT NCT03329508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03329508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.
Lead sponsor
Pharma Two B Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 19, 2018
Completion date
October 31, 2021
Enrollment
544 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

early parkinson's disease, parkinson disease